Figure 1: Overall survival (OS) of the present cohort treated comprehensively including AFTV and the historical control cohorts in Japan. Line 1, the present cohort () with median OS, 60.0 months. Lines 2, 3, and 4, Japanese historical controls taken from Koizumi et al., Figure in [19]. Line 2, patients with solitary sternal metastasis (), median OS, 39.5 months. Line 3, patients with solitary metastatic bone lesion other than sternum (), median OS, 41.4 months. Line 4, patients with multiple metastatic bone lesions (), median OS, 22.6 months.